Skystar Bio-pharmaceutical Co. (fka SKBI)

[236T568]

SKBI suspension delayed until Dec. 3rd NASDAQ delisting hearing


http://money.cnn.com/news/newsfeeds/articles/marketwire/1227156.htm

Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted

Marketwired
November 06, 2015: 09:00 AM ET

Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on November 4, 2015 it received a letter from the Nasdaq Hearings Panel that granted the request of Skystar Bio-Pharmaceutical Company to extend the automatic 15-day stay of suspension from The Nasdaq Stock Market, until the hearing on the merits scheduled for December 3, 2015, and a determination regarding the Company's listing status.

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit www.skystarbio-pharmaceutical.com.
Safe Harbor Statements
When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company's ability to complete its IgG kit effort as well as other related efforts at the Huxian facilities, the Company's ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company's ability to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.